Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Catalent, Inc. and Perrigo Company plc, two industry giants, have shown distinct approaches to optimizing these costs over the past decade. From 2014 to 2023, Catalent, Inc. has seen a steady increase in SG&A expenses, rising by approximately 179%, reflecting their aggressive expansion and investment strategies. In contrast, Perrigo Company plc's SG&A expenses have increased by about 89% over the same period, indicating a more conservative approach.

While Catalent's expenses peaked in 2024, Perrigo's data for that year remains unavailable, leaving room for speculation on their strategic moves. This comparison highlights the diverse strategies companies employ to balance growth and cost management, offering valuable insights for investors and industry analysts alike.